person · Reporting owner

ZACCARDELLI DAVID

Disclosed activity across 5 companies

Tapewire entity: 31235
SEC CIK: 0001627642

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249	Director	June 11, 2019	June 12, 2019
SAB Biotherapeutics, Inc.SABS · Entity 5816	Director	January 05, 2026	January 07, 2026
Vor Biopharma Inc.VOR · Entity 4763	Director	July 07, 2026	July 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

MELINTA THERAPEUTICS, INC. /NEW/

Report date June 11, 2019 · Filed June 12, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Melinta Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	30,000	Reported balance After 2019-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date.

SAB Biotherapeutics, Inc.

Report date January 05, 2026 · Filed January 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2036-01-05	Direct	240,000	Reported balance After 2026-01-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-05 · Grant · Acquired 240,000 · Balance 240,000 F1: Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029. F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029.

F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

Vor Biopharma Inc.

Report date July 07, 2026 · Filed July 09, 2026

This filing explicitly reported no securities owned.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Dova Pharmaceuticals Inc.

Report date November 12, 2019 · Filed November 12, 2019

Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2019-11-12 transaction · row 1 1 source row Row 1 · 2019-11-12 · Disposition to issuer · Disposed 76,647 · Balance 0 F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.07 · Expires 2018-12-18	Direct	0	Reported balance After 2019-11-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-12 · Disposition to issuer · Disposed 1,000,000 · Balance 0 F2: This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $21,430,000.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.

F2: This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $21,430,000.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.

Verona Pharma plc

Report date October 07, 2025 · Filed October 08, 2025

Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	0	Last balance in matching sequence After 2025-10-07 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2025-10-07 · Disposition to issuer · Disposed 12,176,144 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Row 2 · 2025-10-07 · Exercise / conversion · Acquired 3,285,280 · Balance 3,285,280 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration. Row 3 · 2025-10-07 · Disposition to issuer · Disposed 3,285,280 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration.
Restricted Share UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-10-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-10-07 · Exercise / conversion · Disposed 800,000 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Restricted Share UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-10-07 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-10-07 · Exercise / conversion · Disposed 389,792 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Restricted Share UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-10-07 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-10-07 · Exercise / conversion · Disposed 445,536 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Restricted Share UnitSEC Table II · derivative / convertible security	Direct	1,649,952	Reported balance After 2025-10-07 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-10-07 · Grant · Acquired 1,649,952 · Balance 1,649,952 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
Restricted Share UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-10-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-10-07 · Exercise / conversion · Disposed 1,649,952 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.

F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").

F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").

F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.

F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.

F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 22, 2024 Filed Oct 23, 2024 00:46 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	157,912	$4.39	$692,728.36	Disclosure SEC source: 0001104659-24-110659 · tm2426639-2_4seq1.xml · nonDerivative · entry 3 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,736,552 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 8, 2024. F5 · price: The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.375 to $4.4438 per Ordinary Share, inclusive (or $35.00 to $35.55 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F6 · balance_after: Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 11,911,552 Ordinary Shares underlying 1,488,944 ADSs. Read SEC document
October 21, 2024 Filed Oct 23, 2024 00:46 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	110,456	$4.38	$483,753.10	Disclosure SEC source: 0001104659-24-110659 · tm2426639-2_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,894,464 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 8, 2024. F4 · price: The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.3750 to $4.3913 per Ordinary Share, inclusive (or $35.00 to $35.13 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
October 18, 2024 Filed Oct 23, 2024 00:46 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	245,784	$4.38	$1,076,755.13	Disclosure SEC source: 0001104659-24-110659 · tm2426639-2_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,004,920 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 8, 2024. F3 · price: The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $4.3750 to $4.4063 per Ordinary Share, inclusive (or $35.00 to $35.25 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
September 11, 2024 Filed Sep 13, 2024 20:15 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	600,000	$3.76	$2,254,320.00	Disclosure SEC source: 0001104659-24-099794 · tm2423975-2_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,250,704 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 8, 2024. F3 · price: The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $3.75 to $3.7888 per Ordinary Share, inclusive (or $30.00 to $30.31 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F4 · balance_after: Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 12,425,704 Ordinary Shares underlying 1,553,213 ADSs. Read SEC document
August 13, 2024 Filed Aug 14, 2024 20:16 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	8,216	$3.25	$26,702.00	Disclosure SEC source: 0001104659-24-089644 · tm2421466d3_4seq1.xml · nonDerivative · entry 3 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,850,704 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 8, 2024. F3 · price: The price reported represents the ADS sale price on the Nasdaq Stock Market LLC divided by eight (8). F5 · balance_after: Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 13,025,704 Ordinary Shares underlying 1,628,213 ADSs. Read SEC document
August 13, 2024 Filed Aug 14, 2024 20:16 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	390,184	$3.20	$1,248,978.98	Disclosure SEC source: 0001104659-24-089644 · tm2421466d3_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,858,920 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 8, 2024. F4 · price: The price reported represents a weighted average price of the ADSs divided by eight (8). The securities were sold in multiple transactions at prices ranging from $3.125 to $3.246875 per Ordinary Share, inclusive (or $25.00 to $25.99 per ADS, inclusive). The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. Read SEC document
August 12, 2024 Filed Aug 14, 2024 20:16 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	1,600	$3.13	$5,008.00	Disclosure SEC source: 0001104659-24-089644 · tm2421466d3_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,249,104 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 instruction adopted on March 8, 2024. F3 · price: The price reported represents the ADS sale price on the Nasdaq Stock Market LLC divided by eight (8). Read SEC document
August 07, 2024 Filed Aug 9, 2024 23:13 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	314,800	$2.62	$824,776.00	Disclosure SEC source: 0001104659-24-087930 · tm2421367-3_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,250,704 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F3 · shares: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of the Performance Restricted Share Units described in footnote 2 above. F4 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on August 6, 2024 divided by eight (8). F5 · balance_after: Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 13,425,704 Ordinary Shares underlying 1,678,213 ADSs. Read SEC document
August 07, 2024 Filed Aug 9, 2024 23:13 UTC	Verona Pharma plc VRNA · Entity 74409	GrantOrdinary Shares	800,000	$0.00	$0.00	Disclosure SEC source: 0001104659-24-087930 · tm2421367-3_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,565,504 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents an award of Ordinary Shares upon vesting of Performance Restricted Share Units in connection with the Issuer's first commercial sale of ensifentrine. Read SEC document
August 07, 2024 Filed May 2, 2025 00:58 UTC	Verona Pharma plc VRNA · Entity 74409	GrantRestricted Share Units · Derivative	1,200,000	$0.00	$0.00	Disclosure SEC source: 0001104659-25-043647 · tm2513834-4_4seq1.xml · derivative · entry 3 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,200,000 Underlying: Ordinary Shares · 1,200,000 shares Expires not disclosed F5 · security: Represents an award of performance-based Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"), which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F5 · derivative.exercise_price: Represents an award of performance-based Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"), which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F5 · shares: Represents an award of performance-based Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"), which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6 · derivative.exercise_date: The RSUs were earned upon the satisfaction of the performance condition in connection with the Issuer's first commercial sale of ensifentrine. Following the satisfaction of the performance condition, the RSUs vest in equal quarterly installments on each of May 1, 2025, August 1, 2025, November 1, 2025, February 1, 2026, May 1, 2026 and August 1, 2026 subject to the Reporting Person's continued service to the Issuer on each vesting date. F5 · derivative.expiration_date: Represents an award of performance-based Restricted Share Units ("RSUs") covering American Depositary Shares ("ADSs"), which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F1 · derivative.underlying: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Read SEC document
August 01, 2024 Filed Aug 6, 2024 01:29 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	88,544	$2.83	$250,800.88	Disclosure SEC source: 0001104659-24-086002 · tm2420861-2_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,765,504 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F2 · shares: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on July 31, 2024 divided by eight (8). F4 · balance_after: Consists of (i) 2,825,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 353,125 ADSs); and (ii) 12,940,504 Ordinary Shares underlying 1,617,563 ADSs. Read SEC document
May 01, 2024 Filed May 3, 2024 23:19 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	88,544	$1.93	$171,005.03	Disclosure SEC source: 0001104659-24-057113 · tm2413470-1_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,854,048 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F2 · shares: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on April 30, 2024 divided by eight (8). F4 · balance_after: Consists of (i) 3,050,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 381,250 ADSs); and (ii) 12,804,048 Ordinary Shares underlying 1,600,506 ADSs. Read SEC document
February 01, 2024 Filed Feb 5, 2024 23:11 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	480,200	$2.29	$1,101,482.76	Disclosure SEC source: 0001104659-24-010788 · tm245245-4_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,942,592 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F2 · shares: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 31, 2024 divided by eight (8). F4 · balance_after: Consists of (i) 3,275,000 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 409,375 ADSs); and (ii) 12,667,592 Ordinary Shares underlying 1,583,449 ADSs. Read SEC document
November 01, 2023 Filed Nov 4, 2023 00:09 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	809,008	$1.74	$1,410,748.15	Disclosure SEC source: 0001104659-23-114405 · tm2329834-2_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,422,792 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F2 · shares: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 31, 2023 divided by eight (8). F4 · balance_after: Consists of (i) 4,655,928 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 581,991 ADSs); and (ii) 11,766,864 Ordinary Shares underlying 1,470,858 ADSs. Read SEC document
October 20, 2023 Filed Oct 24, 2023 20:06 UTC	Verona Pharma plc VRNA · Entity 74409	GrantOrdinary Shares	800,000	$0.00	$0.00	Disclosure SEC source: 0001104659-23-111094 · tm2329036-4_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,231,800 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · shares: Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 200,000 RSUs vesting on November 1, 2024 and the balance vesting in 12 equal quarterly installments thereafter. F3 · balance_after: Consists of (i) 6,711,840 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 838,980 ADSs); and (ii) 10,519,960 Ordinary Shares underlying 1,314,995 ADSs. Read SEC document
August 07, 2023 Filed Aug 8, 2023 01:17 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	8,616	$2.47	$21,263.43	Disclosure SEC source: 0001104659-23-088492 · tm2323103-3_4seq1.xml · nonDerivative · entry 3 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,431,800 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction entered into on March 24, 2022 solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). F4 · balance_after: Consists of (i) 5,911,840 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 738,980 ADSs); and (ii) 10,519,960 Ordinary Shares underlying 1,314,995 ADSs. Read SEC document
August 04, 2023 Filed Aug 8, 2023 01:17 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	150,000	$2.50	$374,880.00	Disclosure SEC source: 0001104659-23-088492 · tm2323103-3_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,440,416 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction entered into on March 24, 2022 solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). Read SEC document
August 03, 2023 Filed Aug 8, 2023 01:17 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	117,272	$2.54	$297,753.61	Disclosure SEC source: 0001104659-23-088492 · tm2323103-3_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,590,416 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction entered into on March 24, 2022 solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). Read SEC document
August 02, 2023 Filed Aug 4, 2023 00:29 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	73,704	$2.59	$191,114.47	Disclosure SEC source: 0001104659-23-087441 · tm2322845-2_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,707,688 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction entered into on March 24, 2022 solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). F4 · balance_after: Consists of (i) 5,911,840 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 738,980 ADSs); and (ii) 10,795,848 Ordinary Shares underlying 1,349,481 ADSs. Read SEC document
August 01, 2023 Filed Aug 4, 2023 00:29 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	105,944	$2.68	$283,823.98	Disclosure SEC source: 0001104659-23-087441 · tm2322845-2_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,781,392 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction entered into on March 24, 2022 solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). Read SEC document
May 01, 2023 Filed May 3, 2023 23:46 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	455,536	$2.58	$1,173,415.18	Disclosure SEC source: 0001104659-23-055646 · tm2314588-1_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,887,336 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction entered into on May 24, 2022 solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). F4 · balance_after: Consists of (i) 7,067,760 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 883,470 ADSs); and (ii) 9,819,576 Ordinary Shares underlying 1,227,447 ADSs. Read SEC document
February 01, 2023 Filed Feb 3, 2023 23:18 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	432,928	$2.56	$1,107,083.48	Disclosure SEC source: 0001104659-23-010734 · tm235387-3_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,342,872 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). F4 · balance_after: Consists of (i) 8,223,680 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,027,960 ADSs); and (ii) 9,119,192 Ordinary Shares underlying 1,139,899 ADSs. Read SEC document
December 20, 2022 Filed Dec 21, 2022 21:06 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	600,000	$2.12	$1,269,600.00	Disclosure SEC source: 0001104659-22-129085 · tm2233201-2_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,775,800 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 25, 2022. F3 · price: The price reported represents the weighted average sale price of the ADSs divided by eight (8). These shares were sold in multiple transactions at prices ranging from $2.065 to $2.1688, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. F4 · balance_after: Consists of (i) 9,463,200 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,182,900 ADSs); and (ii) 8,312,600 Ordinary Shares underlying 1,039,075 ADSs. Read SEC document
November 01, 2022 Filed Nov 3, 2022 20:06 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	32,904	$1.67	$55,035.23	Disclosure SEC source: 0001104659-22-114416 · tm2229640-3_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,375,800 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units. F5 · price: The price reported represents the sale price of the ADSs divided by eight (8). F6 · balance_after: Consists of (i) 9,463,200 Ordinary Shares underlying RSUs (which are represented by 1,182,900 ADSs); and (ii) 8,912,600 Ordinary Shares underlying 1,114,075 ADSs. Read SEC document
November 01, 2022 Filed Nov 3, 2022 20:06 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	454,856	$1.60	$727,769.60	Disclosure SEC source: 0001104659-22-114416 · tm2229640-3_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,408,704 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 31, 2022 divided by eight (8). Read SEC document
September 26, 2022 Filed Sep 28, 2022 20:05 UTC	Verona Pharma plc VRNA · Entity 74409	GrantOrdinary Shares	3,600,000	$0.00	$0.00	Disclosure SEC source: 0001104659-22-103709 · tm2226815-1_4seq.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,863,560 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · shares: Represents an award of Restricted Share Units ("RSUs"), each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer. The RSUs vest over four years, with 900,000 RSUs vesting on November 1, 2023 and the balance vesting in 12 equal quarterly installments thereafter. F3 · balance_after: Consists of (i) 10,702,720 Ordinary Shares underlying RSUs (which are represented by 1,337,840 ADSs); and (ii) 8,160,840 Ordinary Shares underlying 1,020,105 ADSs. Read SEC document
August 09, 2022 Filed Aug 12, 2022 01:46 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	600,000	$1.75	$1,050,000.00	Disclosure SEC source: 0001104659-22-089568 · tm2223116-2_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,263,560 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 25, 2022. F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). F4 · balance_after: Consists of (i) 7,102,720 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 887,840 ADSs); and (ii) 8,160,840 Ordinary Shares underlying 1,020,105 ADSs. Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:12 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	32,904	$0.70	$23,026.22	Disclosure SEC source: 0001104659-22-085630 · tm2222419-4_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,863,560 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units. F5 · price: The price reported represents the sale price of the ADSs divided by eight (8). F6 · balance_after: Consists of (i) 7,102,720 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 887,840 ADSs); and (ii) 8,760,840 Ordinary Shares underlying 1,095,105 ADSs. Read SEC document
August 01, 2022 Filed Aug 3, 2022 20:12 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	454,864	$0.67	$305,896.04	Disclosure SEC source: 0001104659-22-085630 · tm2222419-4_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,896,464 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on July 29, 2022 divided by eight (8). Read SEC document
May 03, 2022 Filed May 5, 2022 23:20 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	32,904	$0.50	$16,307.22	Disclosure SEC source: 0001104659-22-056608 · tm2214628-3_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,351,328 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover taxes in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the sale price of the ADSs divided by eight (8). F4 · balance_after: Consists of (i) 8,342,256 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,042,782 ADSs); and (ii) 8,009,072 Ordinary Shares underlying 1,001,134 ADSs. Read SEC document
May 01, 2022 Filed May 4, 2022 00:17 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	454,864	$0.52	$237,666.44	Disclosure SEC source: 0001104659-22-055447 · tm2214387-1_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,384,232 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on April 29, 2022 divided by eight (8). F4 · balance_after: Consists of (i) 8,342,256 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,042,782 ADSs); and (ii) 8,041,976 Ordinary Shares underlying 1,005,247 ADSs. Read SEC document
February 03, 2022 Filed Feb 3, 2022 22:56 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	52,056	$0.73	$37,771.83	Disclosure SEC source: 0001104659-22-011440 · tm225347-3_4seq1.xml · nonDerivative · entry 3 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,839,096 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F5 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. F6 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.7150 to $0.7413. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 5. F7 · balance_after: Consists of (i) 9,581,792 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,197,724 ADSs); and (ii) 7,257,304 Ordinary Shares underlying 907,163 ADSs. Read SEC document
February 01, 2022 Filed Feb 3, 2022 22:56 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	288,648	$0.78	$224,077.44	Disclosure SEC source: 0001104659-22-011440 · tm225347-3_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,891,152 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F3 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F4 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 31, 2022 divided by eight (8). Read SEC document
February 01, 2022 Filed Feb 3, 2022 22:56 UTC	Verona Pharma plc VRNA · Entity 74409	GrantOrdinary Shares	334,448	$0.75	$249,999.88	Disclosure SEC source: 0001104659-22-011440 · tm225347-3_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,179,800 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on January 28, 2022 divided by eight (8). Read SEC document
November 02, 2021 Filed Nov 3, 2021 23:52 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	52,056	$0.64	$33,373.10	Disclosure SEC source: 0001104659-21-133857 · tm2131837-3_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,845,352 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. F5 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.6525 to $0.6313. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 5. F6 · balance_after: Consists of (i) 10,535,528 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,316,941 ADSs); and (ii) 6,309,824 Ordinary Shares underlying 788,728 ADSs. Read SEC document
November 01, 2021 Filed Nov 3, 2021 23:52 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	454,848	$0.64	$291,102.72	Disclosure SEC source: 0001104659-21-133857 · tm2131837-3_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,897,408 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on October 29, 2021 divided by eight (8). Read SEC document
August 04, 2021 Filed Aug 5, 2021 00:12 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	18,400	$0.74	$13,674.88	Disclosure SEC source: 0001104659-21-100281 · tm2124077-4_4seq1.xml · nonDerivative · entry 3 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,369,912 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. F6 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.7288 to $0.7538. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 6. F7 · balance_after: Consists of (i) 11,823,712 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,477,964 ADSs); and (ii) 5,546,200 Ordinary Shares underlying 693,275 ADSs. Read SEC document
August 03, 2021 Filed Aug 5, 2021 00:12 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	16,000	$0.76	$12,209.60	Disclosure SEC source: 0001104659-21-100281 · tm2124077-4_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,388,312 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. F5 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.75 to $0.79. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 5. Read SEC document
August 03, 2021 Filed Aug 10, 2021 00:58 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	17,656	$0.75	$13,284.37	Disclosure SEC source: 0001104659-21-102403 · tm2124631-10_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,352,256 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.7338 to $0.7813. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. F4 · balance_after: Consists of (i) 11,823,712 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,477,964 ADSs); and (ii) 5,528,544 Ordinary Shares underlying 691,068 ADSs. Read SEC document
August 01, 2021 Filed Aug 5, 2021 00:12 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	454,848	$0.79	$357,055.68	Disclosure SEC source: 0001104659-21-100281 · tm2124077-4_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,404,312 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on July 30, 2021 divided by eight (8). Read SEC document
May 04, 2021 Filed May 5, 2021 20:06 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	52,056	$0.81	$41,925.90	Disclosure SEC source: 0001104659-21-061710 · tm2115267-2_4seq1.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,859,160 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported Restricted Share Units. F5 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $0.7813 to $0.8688. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. F6 · balance_after: Consists of (i) 13,111,912 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 1,638,989 ADSs); and (ii) 4,747,248 Ordinary Shares underlying 593,406 ADSs. Read SEC document
May 03, 2021 Filed May 5, 2021 20:06 UTC	Verona Pharma plc VRNA · Entity 74409	Tax withholdingOrdinary Shares	2,139,632	$0.89	$1,898,923.40	Disclosure SEC source: 0001104659-21-061710 · tm2115267-2_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,911,216 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: Represents the number of Ordinary Shares withheld to satisfy the tax withholding obligation in connection with the vesting of certain previously reported Restricted Share Units. F3 · price: The price reported represents the closing price of the Issuer's ADSs on the Nasdaq Stock Market LLC on May 3, 2021 divided by eight (8). Read SEC document
March 01, 2021 Filed Mar 4, 2021 01:03 UTC	Verona Pharma plc VRNA · Entity 74409	SaleOrdinary Shares	43,392	$1.14	$49,627.43	Disclosure SEC source: 0001104659-21-031699 · tm218588-3_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,050,848 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the settlement of Restricted Share Units. F3 · price: The price reported is a weighted average price, and is based on the sale price of the ADSs divided by eight (8). The securities were sold in multiple transactions at per share prices ranging from $1.1188 to $1.1575. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote 3. F4 · balance_after: Consists of (i) 19,023,792 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 2,377,974 ADSs); and (ii) 1,027,056 Ordinary Shares underlying 128,382 ADSs. Read SEC document
January 28, 2021 Filed Feb 2, 2021 01:54 UTC	Verona Pharma plc VRNA · Entity 74409	GrantOrdinary Shares	529,104	$0.00	$0.00	Disclosure SEC source: 0001104659-21-010411 · tm214905-2_4seq1.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,094,240 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2 · balance_after: Consists of (i) 19,201,992 Ordinary Shares underlying Restricted Share Units, each of which represents a contingent right to receive one (1) Ordinary Share of the Issuer (which are represented by 2,400,249 ADSs); and (ii) 892,248 Ordinary Shares represented by 111,531 ADSs. Read SEC document
November 12, 2019 Filed Nov 12, 2019 16:42 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	1,000,000	Not disclosed Strike: $6.07	Not disclosed	Disclosure SEC source: 0001209191-19-056047 · doc4.xml · derivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000,000 shares Expires 2018-12-18 F2 · price: This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $21,430,000.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. F2 · derivative.exercise_date: This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $21,430,000.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. Read SEC document
November 12, 2019 Filed Nov 12, 2019 16:42 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	Disposition to issuerCommon Stock	76,647	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-19-056047 · doc4.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. F1 · price: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. Read SEC document
October 01, 2019 Filed Oct 2, 2019 16:21 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	SaleCommon Stock	5,275	$27.90	$147,172.50	Disclosure SEC source: 0001562180-19-005059 · primarydocument.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,647 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.84 to $28.00 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document
July 02, 2019 Filed Jul 3, 2019 16:24 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	SaleCommon Stock	4,551	$16.22	$73,817.22	Disclosure SEC source: 0001209191-19-041095 · doc4.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,922 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.09 to $16.50 inclusive. Read SEC document
July 02, 2019 Filed Jul 3, 2019 16:24 UTC	Dova Pharmaceuticals Inc. DOVA · Entity 153784	SaleCommon Stock	5,899	$15.73	$92,791.27	Disclosure SEC source: 0001209191-19-041095 · doc4.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,473 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person with the intent to cover withholding taxes in connection with the settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.09 to $16.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) and (3) to this Form 4. Read SEC document
June 11, 2019 Filed Jun 12, 2019 17:36 UTC	MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249	GrantMelinta Restricted Stock Units · Derivative	30,000	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001461993-19-000030 · wf-form4_156036099405068.xml · derivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Melinta Common Stock · 30,000 shares Expires not disclosed F1 · derivative.exercise_date: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date. F1 · derivative.expiration_date: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.